J&J Expects Revenue Growth Despite Stelara Biosimilars, IRA Impact

 
• By Joseph Haas

Innovative medicine grew 4% during Q4 2024 and brought in $57bn during the full year, one year ahead of internal projections. Spravato topped the blockbuster mark in its fifth year on market.

J&J predicts 2025 revenue growth despite the impact of Stelara biosimilars • Source: Shutterstock

More from Earnings

More from Strategy